TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: European Post Market Study: A Prospective, Randomized, Controlled, Multicenter Study to Evaluate the Performance of the IBV Valve System for the Treatment of Severe Emphysema
Brief Summary: The objective of this randomized, blinded, multicenter, controlled study is to compare the performance of the IBV Valve System (treatment group) to a control group receiving a sham bronchoscopy procedure without valve placement.


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel | Intervention Type: DRUG; Name: Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel; Assigned to Arm(s): Group 1, Group 2
B: Arm Label: Medical management; Type: NO_INTERVENTION; Interventions: Device: IBV Valve | Intervention Type: DEVICE; Name: IBV Valve; Assigned to Arm(s): Medical management
C: Arm Label: Treatment plus Optimal Medical Therapy; Type: EXPERIMENTAL; Interventions: Device: InterVapor® treatment plus Optimal Medical Therapy | Arm Label: Optimal Medical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Optimal Medical Therapy | Intervention Type: DEVICE; Name: InterVapor® treatment plus Optimal Medical Therapy; Assigned to Arm(s): Treatment plus Optimal Medical Therapy | Intervention Type: OTHER; Name: Optimal Medical Therapy; Assigned to Arm(s): Optimal Medical Therapy
D: Arm Label: Lung volume reduction surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lung volume reduction surgery | Arm Label: No lung volume reduction surgery; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Lung volume reduction surgery; Assigned to Arm(s): Lung volume reduction surgery

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Seroquel XR for the Management of Borderline Personality Disorder (BPD)
Brief Summary: The Primary objective of this study is to evaluate Seroquel XR in the treatment of borderline personality disorder (BPD). As in many initial randomized control trials, the study will be of relatively short duration - 8 weeks - to assess effectiveness and safety while maximizing retention. The specific aim is to determine if Seroquel XR is superior to placebo. The primary outcome measure will be a statistically significant difference between Seroquel XR compared to placebo on the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD), an objective rating scale that addresses the severity of Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) symptoms of the illness. As there is the recent development of an extended release form of Seroquel (Seroquel XR) (Schulz et al. 2007), the new compound may offer several advantages in this study. Therefore, the hypothesis of this study is that both doses of Seroquel XR (see below) will be superior to placebo in an 8-week randomized trial as assessed by the ZAN-BPD.

To achieve the Primary Objective of this study, two doses of Seroquel XR will be tested - 150 mg/d and 300 mg/d. Thus, the study will be able to assess the effect of Seroquel XR compared to placebo and to explore a dose effect.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: Behavioral: Dialectical Cognitive Therapy | Intervention Type: BEHAVIORAL; Name: Dialectical Cognitive Therapy; Assigned to Arm(s): 1
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: quetiapine extended-release | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: quetiapine extended-release | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: quetiapine extended-release; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
C: Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Other: Other | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Other; Assigned to Arm(s): Experimental Arm
D: Arm Label: Mindfulness skills; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness skills training | Arm Label: Interpersonal effectiveness skills; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interpersonal Effectiveness skills training | Intervention Type: BEHAVIORAL; Name: Mindfulness skills training; Assigned to Arm(s): Mindfulness skills | Intervention Type: BEHAVIORAL; Name: Interpersonal Effectiveness skills training; Assigned to Arm(s): Interpersonal effectiveness skills

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Seroquel XR for the Management of Borderline Personality Disorder (BPD)
Brief Summary: The Primary objective of this study is to evaluate Seroquel XR in the treatment of borderline personality disorder (BPD). As in many initial randomized control trials, the study will be of relatively short duration - 8 weeks - to assess effectiveness and safety while maximizing retention. The specific aim is to determine if Seroquel XR is superior to placebo. The primary outcome measure will be a statistically significant difference between Seroquel XR compared to placebo on the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD), an objective rating scale that addresses the severity of Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) symptoms of the illness. As there is the recent development of an extended release form of Seroquel (Seroquel XR) (Schulz et al. 2007), the new compound may offer several advantages in this study. Therefore, the hypothesis of this study is that both doses of Seroquel XR (see below) will be superior to placebo in an 8-week randomized trial as assessed by the ZAN-BPD.

To achieve the Primary Objective of this study, two doses of Seroquel XR will be tested - 150 mg/d and 300 mg/d. Thus, the study will be able to assess the effect of Seroquel XR compared to placebo and to explore a dose effect.


Options:
A: Arm Label: ASAP Treatment and Brite; Type: EXPERIMENTAL; Interventions: Behavioral: As Safe As Possible, Behavioral: Brite | Arm Label: Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: As Safe As Possible; Assigned to Arm(s): ASAP Treatment and Brite | Intervention Type: BEHAVIORAL; Name: Brite; Assigned to Arm(s): ASAP Treatment and Brite | Intervention Type: BEHAVIORAL; Name: Treatment as Usual; Assigned to Arm(s): Treatment as Usual
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: General Psychiatric Management | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behaviour Therapy | Intervention Type: BEHAVIORAL; Name: General Psychiatric Management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy; Assigned to Arm(s): 2
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: quetiapine extended-release | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: quetiapine extended-release | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: quetiapine extended-release; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: meditation; Type: EXPERIMENTAL; Interventions: Behavioral: Central Meditation and Imagery Therapy | Arm Label: wait list; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Central Meditation and Imagery Therapy; Assigned to Arm(s): meditation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prophylaxis of Venous Thromboembolism in Patients With a Nonsurgical Fracture of the Lower Extremity Immobilised in a Below-Knee Plaster Cast
Brief Summary: Objective:

The purpose of this study is to determine the need for thromboprophylaxis in patients with a fracture of the lower extremity being treated conservatively in a below-knee plaster cast and to assess if both of the two tested prophylactic treatments are effective for this indication.

Hypothesis:

Nadroparine and Fondaparinux are both effective in preventing a thromboembolic event in patients with a nonsurgical fracture of a lower extremity immobilised in a below-knee plaster cast.


Options:
A: Arm Label: LMWH (Fragmin, dalteparin); Type: ACTIVE_COMPARATOR; Interventions: Drug: LMWH (Fragmin, dalteparin) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated Heparin | Intervention Type: DRUG; Name: LMWH (Fragmin, dalteparin); Assigned to Arm(s): LMWH (Fragmin, dalteparin) | Intervention Type: DRUG; Name: Unfractionated Heparin; Assigned to Arm(s): 2
B: Arm Label: LMWH; Type: EXPERIMENTAL; Interventions: Drug: LMWH | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: LMWH; Assigned to Arm(s): LMWH
C: Intervention Type: DRUG; Name: Low Molecular Weight Heparin (dalteparin); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Nadroparin; Type: EXPERIMENTAL; Interventions: Drug: Nadroparin | Arm Label: Fondaparinux; Type: EXPERIMENTAL; Interventions: Drug: Fondaparinux | Intervention Type: DRUG; Name: Nadroparin; Assigned to Arm(s): Nadroparin | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive Behavioral Treatment of Insomnia in Posttraumatic Stress Disorder
Brief Summary: This study will test the effectiveness of cognitive behavioral therapy for insomnia in treating sleep disturbances in people with post-traumatic stress disorder.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Cognitive Behavioral Treatment for Insomnia (CBT-I) | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cognitive Behavioral Treatment for Insomnia (CBT-I); Assigned to Arm(s): 1
B: Arm Label: ROSE Program; Type: EXPERIMENTAL; Interventions: Behavioral: ROSE Program | Arm Label: Control Condition; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ROSE Program; Assigned to Arm(s): ROSE Program
C: Arm Label: Online intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Online intervention | Arm Label: Psycho-educational website; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psycho-educational website | Intervention Type: BEHAVIORAL; Name: Online intervention; Assigned to Arm(s): Online intervention | Intervention Type: BEHAVIORAL; Name: Psycho-educational website; Assigned to Arm(s): Psycho-educational website
D: Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Processing Therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Written Exposure; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 4 Study of the Effect of Human Recombinant Erythropoietin at the Time of Reperfusion in Patients With Acute Myocardial Infarction
Brief Summary: The purpose of this study is to investigate the effect of intravenous human recombinant erythropoietin on the reperfusion injury at primary percutaneous coronary intervention in patients with acute myocardial infarction.


Options:
A: Arm Label: EPO group; Type: EXPERIMENTAL; Interventions: Drug: EPO group | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: EPO group; Assigned to Arm(s): EPO group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo group
B: Arm Label: PCI only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: EPO; Type: EXPERIMENTAL; Interventions: Drug: human recombinant erythropoietin | Intervention Type: DRUG; Name: human recombinant erythropoietin; Assigned to Arm(s): EPO
C: Intervention Type: DRUG; Name: Erythropoietin; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: G-CSF with/without darbepoetin, peripheral blood stem cell infusion; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once- Monthly Administration of Subcutaneous CERA for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anemia
Brief Summary: This single arm study will assess the efficacy, safety and tolerability of once monthly administration of subcutaneous Mircera for the maintenance of hemoglobin levels in dialysis patients with chronic renal anemia. Patients will receive subcutaneous Mircera at a starting dose of 120, 200 or 360 micrograms every 4 weeks, calculated from the last weekly dose of epoetin or darbepoetin alfa previously administered. Subsequent doses will be adjusted to maintain hemoglobin levels within the target range. Treatment duration is 56 weeks, and the target sample size is 200 individuals.


Options:
A: Arm Label: C.E.R.A.; Type: ACTIVE_COMPARATOR; Interventions: Drug: comparison between darbepoetin alfa and C.E.R.A. and different administration intervals | Arm Label: Darbepoetin; Type: ACTIVE_COMPARATOR; Interventions: Drug: comparison between darbepoetin alfa and C.E.R.A. and different administration intervals | Intervention Type: DRUG; Name: comparison between darbepoetin alfa and C.E.R.A. and different administration intervals; Assigned to Arm(s): C.E.R.A., Darbepoetin
B: Arm Label: Mircera in Renal Anemia; Type: EXPERIMENTAL; Interventions: Drug: Methoxy polyethylene glycol-epoetin beta | Intervention Type: DRUG; Name: Methoxy polyethylene glycol-epoetin beta; Assigned to Arm(s): Mircera in Renal Anemia
C: Arm Label: C.E.R.A.; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): C.E.R.A.
D: Arm Label: MIRCERA; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): MIRCERA

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Pulmonary Rehabilitation in Interstitial Lung Diseases: a Prospective Randomized Controlled Trial
Brief Summary: Treatment in interstitial lung diseases (ILD) is frequently ineffective. Pulmonary rehabilitation (PR) is an excellent therapeutic option in another chronic lung diseases such as chronic obstructive pulmonary disease (COPD). This prospective randomized controlled study aims to evaluate the short and long-term effects of PR in patients with ILD. For this purpose, 60 ILD patients will be randomly assigned to a PR or a control group.

The investigators hypothesize that PR will improve exercise capacity, increase muscle force, reduce dyspnea and improve quality of life and daily life activities in ILD patients.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Pulmonary Rehabilitation | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pulmonary Rehabilitation; Assigned to Arm(s): 1
B: Arm Label: BIBF 1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): BIBF 1120
C: Arm Label: Nintedanib; Type: EXPERIMENTAL; Interventions: Drug: Nintedanib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Nintedanib; Assigned to Arm(s): Nintedanib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: BIBF 1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): BIBF 1120

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Electrical Muscle Stimulation (EMS), a Preventive and Therapeutic Tool for Critical Illness Polyneuromyopathy (CIPNM)- A Randomized Controlled Parallel Intervention Trial.
Brief Summary: The purpose of this study is to investigate the role of EMS as a preventive and therapeutic tool of CIPNM. The investigators hypothesized that EMS will prevent the development of CIPNM or have a beneficial role as a therapeutic means in case of CIPNM appearance.


Options:
A: Intervention Type: DEVICE; Name: Neuromuscular Electrical stimulator (Cefar rehab 4 pro); Assigned to Arm(s): N/A
B: Arm Label: EMS group; Type: EXPERIMENTAL; Interventions: Procedure: EMS | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: EMS; Assigned to Arm(s): EMS group
C: Arm Label: NMES; Type: EXPERIMENTAL; Interventions: Device: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA) | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Sham | Intervention Type: DEVICE; Name: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA); Assigned to Arm(s): NMES | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): Sham
D: Arm Label: NMES group; Type: EXPERIMENTAL; Interventions: Other: Neuromuscular electrical stimulation, Other: Endurance training, Other: Quadriceps strength training | Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Other: Endurance training, Other: Quadriceps strength training | Intervention Type: OTHER; Name: Neuromuscular electrical stimulation; Assigned to Arm(s): NMES group | Intervention Type: OTHER; Name: Endurance training; Assigned to Arm(s): Control group, NMES group | Intervention Type: OTHER; Name: Quadriceps strength training; Assigned to Arm(s): Control group, NMES group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Electrical Muscle Stimulation (EMS), a Preventive and Therapeutic Tool for Critical Illness Polyneuromyopathy (CIPNM)- A Randomized Controlled Parallel Intervention Trial.
Brief Summary: The purpose of this study is to investigate the role of EMS as a preventive and therapeutic tool of CIPNM. The investigators hypothesized that EMS will prevent the development of CIPNM or have a beneficial role as a therapeutic means in case of CIPNM appearance.


Options:
A: Arm Label: NMES; Type: EXPERIMENTAL; Interventions: Device: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA) | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Sham | Intervention Type: DEVICE; Name: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA); Assigned to Arm(s): NMES | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): Sham
B: Arm Label: EMS group; Type: EXPERIMENTAL; Interventions: Procedure: EMS | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: EMS; Assigned to Arm(s): EMS group
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Traditional management | Arm Label: B; Type: EXPERIMENTAL; Interventions: Procedure: Fast track patient management | Intervention Type: PROCEDURE; Name: Fast track patient management; Assigned to Arm(s): B | Intervention Type: PROCEDURE; Name: Traditional management; Assigned to Arm(s): A
D: Arm Label: Early PT OT; Type: EXPERIMENTAL; Interventions: Procedure: early PT OT | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: early PT OT; Assigned to Arm(s): Early PT OT

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Electrical Muscle Stimulation (EMS), a Preventive and Therapeutic Tool for Critical Illness Polyneuromyopathy (CIPNM)- A Randomized Controlled Parallel Intervention Trial.
Brief Summary: The purpose of this study is to investigate the role of EMS as a preventive and therapeutic tool of CIPNM. The investigators hypothesized that EMS will prevent the development of CIPNM or have a beneficial role as a therapeutic means in case of CIPNM appearance.


Options:
A: Arm Label: Early PT OT; Type: EXPERIMENTAL; Interventions: Procedure: early PT OT | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: early PT OT; Assigned to Arm(s): Early PT OT
B: Arm Label: NMES; Type: EXPERIMENTAL; Interventions: Device: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA) | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Sham | Intervention Type: DEVICE; Name: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA); Assigned to Arm(s): NMES | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): Sham
C: Arm Label: EMS group; Type: EXPERIMENTAL; Interventions: Procedure: EMS | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: EMS; Assigned to Arm(s): EMS group
D: Intervention Type: DRUG; Name: intensive insulin therapy to maintain normoglycemia; Assigned to Arm(s): N/A

Answer: C